Kenneth C. Frazier

CIK: 0001181175

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EIKN

Eikon Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

EIKN
Eikon Therapeutics, Inc.
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
25.9K shares-
EIKN
Eikon Therapeutics, Inc.
Feb 4, 2026
Purchase(P)
Direct
111.1K shares at avg. $18.00$2.0M

		Type	Shares	Price		Ownership
Mar 2, 2026	EIKN Eikon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	25,873	-	-	Direct
Feb 4, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	111,111	$18.00	$1,999,998	Direct

1-2 of 2 transactions

About FRAZIER KENNETH C

FRAZIER KENNETH C (SEC CIK 0001181175) files insider reports with the SEC as Director of Eikon Therapeutics, Inc. (EIKN).

Signal8 holds 3 ownership filings by FRAZIER KENNETH C (1 Form 3, 2 Form 4), filed between Feb 4, 2026 and Mar 4, 2026. Those filings report 2 transactions, from Feb 4, 2026 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on FRAZIER KENNETH C's filings is in MILLBRAE, CA.

Recent filings by FRAZIER KENNETH C

Mar 2, 2026: Grant or award of EIKN derivative securities (Form 4, code A).
Feb 4, 2026: Open-market purchase of EIKN shares (Form 4, code P).

Other insiders filing for Eikon Therapeutics, Inc. (EIKN)

Column Group IV GP, LP, 10% Owner
Francisco Ma. Fatima, Director
Klobuchar Michael A, Chief Operating Officer
Huffines Robert Luther, Director
PERLMUTTER ROGER M
Thorner Benjamin Bruno

How to read Form 4 transaction codes